Healwell AI's Transformation Nears Finish Line with Crucial Quarter Ahead

Healwell AI reports first positive annual adjusted EBITDA after 427% revenue surge, divests non-core assets, and prepares to launch its unified Amadeus AI platform in 2026.

The radical reshaping of Healwell AI is almost complete. Having spent the last year systematically shedding non-core assets, the company now faces the critical task of proving its streamlined, AI-focused business model can deliver consistent, organic growth. The upcoming first-quarter results for 2026 will serve as the first major test of this new corporate identity.

This strategic pivot is underscored by a recent divestiture. In late March, Healwell signed a letter of intent to sell its subsidiary HEAL Access Canada to AI Maverick Intel. The deal, contingent on the buyer demonstrating a positive net working capital of at least $5 million USD at closing, would see Healwell receive 20 million exchangeable shares of the buyer and a secured vendor loan of approximately $5 million USD. A definitive agreement is targeted by May 29, 2026. This move follows a broader divestment strategy that injected roughly CAD 9.7 million into Healwell's coffers in the fourth quarter of 2025 alone.

Financially, the transformation has already yielded dramatic results. For the full year 2025, revenue from continuing operations soared to CAD 103.8 million, a staggering 427% increase from CAD 19.7 million the prior year. The primary driver was the acquisition of Orion Health, finalized on April 1, 2025. More significantly, Healwell reported its first-ever positive adjusted EBITDA for a full year, reaching CAD 2.3 million. The fourth quarter alone swung to an adjusted EBITDA of CAD 1.4 million from a loss of CAD 5 million, marking the third consecutive profitable quarter by this measure. Despite this operational progress, the company posted an IFRS net loss of CAD 39.1 million for 2025. By year-end, Healwell held CAD 18.6 million in cash and equivalents, alongside strategic investments—including a stake in xAI, now part of the SpaceX ecosystem—that it is exploring monetizing.

With the balance sheet largely cleaned up, management's focus has shifted squarely to driving future growth. The centerpiece of this effort is the consolidated Amadeus AI platform, slated for a North American launch in the first half of 2026. This platform will unify Healwell's existing Khure and Pentavere products under a single AI engine powered by its proprietary DARWEN technology, with international expansion planned for late 2026. The Amadeus system, inherited from Orion Health, has already served data for more than 150 million patients across 15 countries.

Commercial momentum is building. The company recently secured a multi-year, multi-million dollar software contract in the US Health Information Exchange segment and has established healthcare data networks in eleven countries. It has also signed initial AI contracts in the Middle East. The scientific foundation for its technology continues to strengthen, with 47 peer-reviewed publications related to the DARWEN platform, the most recent featured in the Journal of Crohn's and Colitis and presented at the ECCO congress on March 12, 2026.

For 2026, Healwell's leadership has set ambitious targets: approximately 50% growth in AI-related revenue and an adjusted EBITDA margin around 10%. The immediate challenge, however, is the first quarter. Management has already flagged Q1 2026 as likely the company's weakest period this year due to seasonal demand patterns. The report, expected in May, must demonstrate Healwell can maintain its streak of positive adjusted EBITDA quarters while showing tangible progress on the Amadeus AI rollout. Success would provide concrete evidence that the corporate overhaul has built a sustainably profitable enterprise, not merely engineered a one-time financial contraction.